StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Bio-Path Trading Up 3.8 %

Shares of NASDAQ:BPTH opened at $0.17 on Wednesday. The stock has a fifty day moving average of $0.46 and a 200-day moving average of $0.78. Bio-Path has a one year low of $0.12 and a one year high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.